Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRUIN-MCL-321: pirtobrutinib versus investigator's choice BTK inhibitor in previously treated BTK inhibitor-naive mantle cell lymphoma
2023-507695-52-00Phase 3Authorised
- Sponsor
- Loxo Oncology
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of pirtobrutinib and ibrutinib in mantle cell lymphoma (MCL) (2 arms), sponsored by Loxo Oncology. Primary endpoint: Progression-free survival. Planned start Mar 2021; status: authorised.
02
Drugs
pirtobrutinibibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2023-507695-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507695-52-00.